A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY-Enhanced 2D-Echo and Magnetic Resonance Imaging
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2019
At a glance
- Drugs Perflutren (Primary)
- Indications Cardiovascular disorders
- Focus Diagnostic use; Registrational
- Acronyms BENEFIT1
- Sponsors Lantheus Medical Imaging
- 24 Oct 2018 Status changed from not yet recruiting to recruiting.
- 01 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 04 Jul 2018 New trial record